Crizanlizumab
- Generic Name
- Crizanlizumab
- Brand Names
- Adakveo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1690318-25-2
- Unique Ingredient Identifier
- L7451S9126
- Background
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickl...
- Indication
Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are ≥16 years old.
- Associated Conditions
- Vaso-occlusive Crisis
- Associated Therapies
- -
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT03264989
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta ., Atlanta, Georgia, United States
🇺🇸University of Maryland Medical Ctr, Baltimore, Maryland, United States
🇺🇸East Carolina University East Carolina University, Greenville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.